A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study To Compare The Pharmacokinetics Of Pf-05221304 In Adult Subjects With Varying Degrees Of Hepatic Impairment Relative To Subjects Without Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Jan 2018 Status changed from not yet recruiting to recruiting.
- 19 Dec 2017 Planned End Date changed from 22 Nov 2018 to 1 Dec 2018.
- 19 Dec 2017 Planned primary completion date changed from 22 Nov 2018 to 1 Dec 2018.